Clinical trials: Diabetic Nephropathies
Type 2 Diabetes, Diabetes Type 2
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
The current protocol plans to enroll participants with youth-onset Type 2 Diabetes (T2D) as well as obese and lean controls from the Renal-HEIR - Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2…
- Conditions
- Type 2 Diabetes, Diabetes Type 2, Diabetic Nephropathies, Nephropathy
- Trial name
- HEIRitage (NCT05530356)
- Testing
- Aminohippurate Sodium Inj 20%, Iohexol Inj 300 MG/ML, Dextran 40
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Colorado, Denver
Diabetic Kidney Disease, Hyperuricemia
Uric Acid Lowering Trial in Youth Onset T2D
Adolescents and young adults with youth-onset type 2 diabetes (T2D) are disproportionally impacted by hyperuricemia compared to non-diabetic peers and youth with type 1 diabetes (T1D).
- Conditions
- Diabetic Kidney Disease, Hyperuricemia, Diabetes, Diabetes Mellitus, Type 2
- Trial name
- ULTRA-T2D (NCT03899883)
- Testing
- Pegloticase 8 MG/ML [Krystexxa]
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Colorado, Denver
Type 1 Diabetes, Diabetic Nephropathy
Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes
The purpose of this study is to determine whether alkalinization of urine uric acid by 2 doses of sodium bicarbonate (1950mg) over 24-hours reduces precipitation and crystallization of urine uric acid over in adults with type 1…
- Conditions
- Type 1 Diabetes, Diabetic Nephropathy, Diabetic Kidney Disease
- Trial name
- Alk-UA (NCT02502071)
- Testing
- sodium bicarbonate
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Colorado, Denver
Chronic Kidney Disease
Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and safety of 25 mg QD lorundrostat (an aldosterone synthase inhibitor [ASI]) in…
- Trial name
- NCT06150924
- Where
- 44 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mineralys Therapeutics Inc.
Diabetes Mellitus, Diabetic Kidney Disease
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study
SGLT2 inhibitors such as ertugliflozin improve blood pressure and kidney outcomes in people living with diabetes through incompletely understood mechanisms, however, not all patients treated with SGLT2 inhibition have improved…
- Conditions
- Diabetes Mellitus, Diabetic Kidney Disease, Hypertension
- Trial name
- DESIGN (NCT05727579)
- Testing
- Salt-Diet and/or Ertugliflozin, Ertugliflozin 15 mg
- Where
- Netherlands
- Volunteers
- 41 people
- Sponsor
- Amsterdam UMC, location VUmc
Diabetic Nephropathy
Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
The purpose of this study is to evaluate the efficacy and safety of Canagliflozin (TA-7284) in Japanese patients with Diabetic Nephropathy, compared with placebo
- Trial name
- NCT03436693
- Testing
- Canagliflozin
- Where
- 26 sites in Japan
- Volunteers
- 308 people
- Sponsor
- Tanabe Pharma Corporation
Diabetic Kidney Disease
Targeting Leukotrienes in Kidney Disease
Diabetic kidney disease (DKD) is associated with significant morbidity and mortality. Identifying new treatments for DKD to be used alone or in combination with other therapies is a high priority.
- Trial name
- NCT05362474
- Testing
- Montelukast
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Colorado, Denver
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
NADPH oxidase enzymes (NOX) have been implicated in the development of several diabetic complications including diabetic nephropathy. GKT137831 is the first in class NOX1/4 inhibitor.
- Trial name
- NCT02010242
- Testing
- GKT137831
- Where
- 48 sites in United States, Australia and 4 more
- Volunteers
- 136 people
- Sponsor
- Calliditas Therapeutics AB
Type 2 Diabetes Mellitus, Chronic Kidney Diseases
A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus
A Phase 2b, study to measure the effect of Cotadutide at different doses versus placebo or comparator (semaglutide) in participants who have Chronic Kidney Disease with Type 2 Diabetes Mellitus.
- Trial name
- NCT04515849
- Testing
- Cotadutide 100 micrograms, Cotadutide 300 micrograms, Cotadutide 600 micrograms
- Where
- 83 sites in Australia, Canada and 6 more
- Volunteers
- 248 people
- Sponsor
- AstraZeneca
Chronic Kidney Disease
A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
The purpose of the study is to evaluate the dose-response efficacy, safety, and pharmacokinetics (PK) of AZD5718 in participants with proteinuric chronic kidney disease.
- Trial name
- NCT04492722
- Testing
- AZD5718, Dapagliflozin 10 mg
- Where
- 111 sites in United States, Argentina and 9 more
- Volunteers
- 613 people
- Sponsor
- AstraZeneca
Heart Failure, Chronic Kidney Disease
Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease
The purpose of the study is to evaluate the efficacy and safety of AZD9977 in combination with dapagliflozin compared with dapagliflozin alone and to assess the dose-response relationship, dapagliflozin alone and 3 doses of…
- Trial name
- MIRACLE (NCT04595370)
- Testing
- AZD9977, Dapagliflozin
- Where
- 156 sites in United States, Belgium and 20 more
- Volunteers
- 153 people
- Sponsor
- AstraZeneca
Diet Modification, Diabetic Kidney Disease
Effect of the Teleconsultation of Renal Nutrition on Renal Function and Glycemic Control in Patients With DKD
The modern era is characterized by progress, development and social and economic globalization. Currently the electronic technology has applications in a wide variety of work areas. A clear example of this, is telemedicine.
- Conditions
- Diet Modification, Diabetic Kidney Disease, Chronic Kidney Diseases
- Trial name
- NCT03344549
- Testing
- Renal nutrition teleconsultation, Face-to-face consultation of renal nutrition
- Where
- Mexico
- Volunteers
- 53 people
- Sponsor
- Hospital Civil Juan I. Menchaca
Diabetic Nephropathies
A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease
This study is open to adults with diabetic kidney disease. The purpose of the study is to find out whether a medicine called BI 685509 improves kidney function. Three different doses of BI 685509 are tested in this study.
- Trial name
- NCT04750577
- Testing
- BI 685509
- Where
- 78 sites in United States, Argentina and 14 more
- Volunteers
- 243 people
- Sponsor
- Boehringer Ingelheim
Diabetic Kidney Disease
A Phase 2b Diabetic Kidney Disease Study
A Phase 2b Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease
- Trial name
- NCT04170543
- Testing
- MEDI3506, Dapagliflozin
- Where
- 97 sites in United States, Argentina and 5 more
- Volunteers
- 609 people
- Sponsor
- AstraZeneca
CKD, Diabetic Kidney Disease
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
This randomized study evaluates the effect of subcutaneous semaglutide /in combination with lifestyle counseling in patients with type 2 diabetes mellitus (T2DM), overweight/obesity, and stage 4-5 chronic kidney disease (CKD) or…
- Conditions
- CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity
- Trial name
- RAISE-KT (NCT04741074)
- Testing
- Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Geisinger Clinic
Diabetic Kidney Disease (DKD)
Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease
This phase 2a, double-blind, randomized, placebo-controlled study will assess the efficacy, safety, tolerability, and pharmacokinetics (PK), of repeat doses of CSL346 in subjects with diabetic kidney disease (DKD) and albuminuria…
- Trial name
- NCT04419467
- Testing
- CSL346
- Where
- 37 sites in United States, Australia and 4 more
- Volunteers
- 114 people
- Sponsor
- CSL Behring
Chronic Kidney Disease
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
The primary objective of this study was to demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to…
- Trial name
- FIDELIO-DKD (NCT02540993)
- Testing
- Finerenone (BAY94-8862)
- Where
- 978 sites in United States, Argentina and 46 more
- Volunteers
- 5,734 people
- Sponsor
- Bayer
Diabetic Kidney Disease
Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease
The primary objective of this study is to evaluate whether selonsertib (SEL) can slow the decline in kidney function in participants with moderate to advanced diabetic kidney disease (DKD).
- Trial name
- MOSAIC (NCT04026165)
- Testing
- SEL
- Where
- 111 sites in United States, Australia and 3 more
- Volunteers
- 384 people
- Sponsor
- Gilead Sciences
Type 2 Diabetes Mellitus With Diabetic Nephropathy
A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria
To evaluate the safety and efficacy of IW-1973 in patients with type 2 diabetes mellitus with albuminuria who are on a stable regimen of renin-angiotensin system inhibitors.
- Trial name
- NCT03217591
- Testing
- IW-1973
- Where
- 54 sites in United States
- Volunteers
- 156 people
- Sponsor
- Akebia Therapeutics
Diabetic Kidney Disease
Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria
The primary objective of this study is to assess the effect of 2 dose levels of TMX-049 on urinary albumin excretion in subjects with Type 2 diabetes and albuminuria (a urinary albumin-to-creatinine ratio (UACR) 200 to 3000 mg/g…
- Trial name
- NCT03449199
- Testing
- TMX-049
- Where
- 55 sites in United States
- Volunteers
- 130 people
- Sponsor
- Teijin America, Inc.